Table 4. Survival and Pathways.

Pathway Name or Other Variable	Coefficient	P-value
Stage 2	1.00	<0.0001
Stage 3	1.56	<0.0001
Cell Cycle (+)	0.37	<0.0001
Notch	0.015	0.91
Hedgehog	0.14	0.09
B-cell	−0.26	0.037
Hypoxia	−0.20	0.11
EGFR	−0.21	0.014
IL-suppressive	0.19	0.20
Cell Cycle (−)	−0.14	0.12
Age	0.035	<0.0001
Stage 2 : Notch	−0.056	0.78
Stage 3 : Notch	0.39	0.043
Stage 2 : B-cell	−0.39	0.11
Stage 3 : B-cell	0.21	0.36
Stage 2 : Hypoxia	0.26	0.17
Stage 3 : Hypoxia	0.42	0.063
Stage 2 : IL-suppressive	0.70	0.0045
Stage 3 : IL-suppressive	0.11	0.61

The cell cycle stimulatory (CC+) pathway gives additional prognostic information beyond standard clinical covariates such as stage and age, where patients with greater expression levels of the CC+ pathway have an increased hazard compared to those with relative underexpression. The B-cell and EGFR pathways also give additional information where patients with relative overexpression of either of these pathways to better although the relationship with the B-cell pathway only exists in stage 1 patients. In addition, stage 3 patients with relative overexpression of the Notch or the response to hypoxia pathway do worse while stage 2 patients with relative overexpression of pathway representing activity of immunosuppressive interleukins did poorer. Variables not listed were dropped during model selection.